HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Other PET Tracers and Prospects for the Future.

Abstract
(18)F FDG-PET has proven its use as a technique in the field of melanoma, but there are valid concerns related to the specificity of (18)F FDG-PET findings and the degree of accuracy we can expect in the assessment of response to new treatment protocols. The main avenues currently being explored for future use in staging and management of melanoma with PET other than FDG include monoclonal antibodies against melanoma-associated antigens, α-MSH analogues, amino acids involved in melanin formation, nicotinamide-based compounds, heterodimeric glycoproteins such as integrins, reporter gene imaging, cell proliferation, and hypoxia tracers.
AuthorsDavid Fuster, Francesca Pons, Domenico Rubello, Abass Alavi
JournalPET clinics (PET Clin) Vol. 6 Issue 1 Pg. 91-7 (Jan 2011) ISSN: 1556-8598 [Print] United States
PMID27156358 (Publication Type: Journal Article)
CopyrightCopyright © 2011 Elsevier Inc. All rights reserved.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: